Latest news with #Contract
Yahoo
a day ago
- Sport
- Yahoo
By skipping practice at OTAs for the second straight year, Lamar Jackson adds to the forfeited bonus that now exceeds one million dollars.
By skipping practice at OTAs for the second straight year, Lamar Jackson adds to the forfeited bonus that now exceeds one million dollars. originally appeared on Athlon Sports. Star quarterback Lamar Jackson may be up for a contract extension with the Baltimore Ravens, but his current deal includes bonus that could still go into effect ... if necessary. Advertisement Jackson has chosen to skip voluntary workouts at Ravens' OTAs for the second consecutive year, now forcing him to miss out on this add-on to his salary. The quarterback's five-year, $260 million contract includes a feature that states he can earn a $750,000 bonus if he attends at least 80 percent of the team's workouts. The agreement is in play for the next three years, as well. But due to his absence, Jackson has now forfeited $1.5 million of bonus over the last two seasons by skipping the team's organized team activities. As Pro Football Talk also notes, Jackson could be at greater risk within his contract terms. Advertisement If he is working out away from the facility - like many expect he is - and gets injured, it would qualify as a "non-football injury" which could "allow the team to not pay him in 2025." Hopefully the Ravens won't have to worry about the situation getting to that point, as they may not be too worried about whether or not he is at these preliminary practices to begin with. If last year is an example, Jackson missing OTAs didn't affect his performance on the field as he guided the Ravens to another division championship and was practically one dropped-pass away from a conference championship berth. However, as the on-field leader and perennial MVP candidate, the expectation is that he would be a full participant in every opportunity to get any inch closer to the dream of hoisting the Lombardi Trophy for the first time - even if that is attending OTAs. Advertisement Plus, he could get three quarters of a million dollars in the process. Or not. Regardless, Jackson is expected to make his first appearance at the upcoming mandatory minicamp. His contract extension is drawing predictions of exceeding the league record for average annual salary ... of course, before practice bonuses. Maybe the Ravens are better off getting ahead of things and excluding those terms from his next contract. Related: Harbaugh Reveals Take on Lamar Jackson Missing Ravens OTAs Related: Healthy Ravens Offense Could 'Terrify' Opponents This story was originally reported by Athlon Sports on Jun 8, 2025, where it first appeared.
The Hill
06-05-2025
- Politics
- The Hill
Democrats didn't have such a great 100 days, either
Whatever troubles President Trump is having right now with his sinking poll numbers, the Democratic Party is still a listing ship — rudderless, leaking, with some crew members trying to patch the hull with explosives. Losing the White House and both houses of Congress was always going to be a disorienting blow. But the Democrats have elevated post-defeat turmoil to an art form. True, after the first 100 days of his presidency, according to the ABC News-Washington Post-Ipsos poll, Trump's approval ratings sank to 39 percent — the lowest of any president in 80 years. But the Democratic congressional leadership, with their measly 27 percent approval rating, managed to beat him to the bottom. Senate Minority Leader Chuck Schumer's (D-N.Y.) 17 percent approval rating is in the Mariana Trench. The Democrats seem powered as much by rage as by political strategy. New York Democrats, for example, unable to stop Trump's dismantling of federal support for electric vehicles, have channeled their fury at — of all things — an electric vehicle manufacturer: Elon Musk's Tesla. To punish Musk they have tried to prevent the company from selling directly to consumers. Instead of raising funds to flip just the heartbreakingly few Republican held-seats needed to win back the House, DNC vice chair David Hogg is raising money to finance primary challenges against Democratic incumbents, which party strategist James Carville called ' insane. ' Rather than deploying messaging that might appeal to the independent voters who swung for Trump, some Democrats running for Congress are — this is not a joke — dropping the f-bomb in their campaign ads, pledging, for example, to 'unf— our country.' Democrats deliver barn-burning speeches, but does anyone really know where they stand on immigration, tariffs, or the economy? Apoplexy may light fires on social media, but it doesn't chart a path to power. Nor is assuming that Trump's declining approval ratings will automatically convert into Democratic votes a serious strategy. If the presidential election were held today, Trump — despite sacking the federal government and behaving as though he were elected to rescue Americans from their own Constitution — would still beat Kamala Harris, albeit by a narrower margin. Democrats had better start thinking boldly. For inspiration, they might look to then-House Minority Whip Newt Gingrich's (R-Ga.) 'Contract With America,' co-authored with Rep. Dick Armey (R-Texas), for the 1994 midterm elections. The Contract promised that if Republicans gained control of the House, they would bring 10 specific bills to a vote. The proposed bills — including an anti-crime 'Taking Back Our Streets Act' and a 'National Security Restoration Act' — each enjoyed over 60 percent support among voters. With impressive discipline, the Contract excluded divisive issues such as abortion and school prayer. The Contract, signed by virtually every Republican House incumbent and challenger, arguably nationalized the midterms and turned them into a referendum on President Bill Clinton. In a stunning comeback, Republicans won the Senate and — after 40 years in the minority wilderness — the House. All politics wasn't local after all. A Contract With America has the virtue of explaining what a party and its candidates stand for but it carries the risk that trying to craft such a platform can expose or even deepen internal divisions. Cue David Hogg saying, 'Sign that, and I'll raise money to primary you.' Democrats, facing a president who is methodically weakening democracy — an existential threat for any minority party — need to summon discipline and boldness. Otherwise, they may find themselves not only out of power, but political roadkill. So, do you think Democrats are up to it?
Yahoo
06-05-2025
- Business
- Yahoo
eClinical Solutions Market Size to Lead USD 40,500 Million by 2034, Growth in the Biopharmaceutical and Pharmaceutical Industry
By development phase, the Phase I segment is projected to experience the highest growth rate in the market between 2024 to 2034. By delivery mode, the on-premises segment is observed to grow at a notable rate during the forecast period. By delivery mode, the web and cloud-based segment accounted the highest market share in 2024. By end use, the pharma & biotech organizations segment is predicted to grow with the fastest CAGR in the market from 2025 to 2034. By end use, the Contract Research Organizations (CROs) segment registered the maximum market share in 2024. By product, the electronic clinical outcome assessment (eCOA) segment is predicted grow at the fastest rate in the market between 2025 and 2034. By product, the clinical trial management system (CTMS) segment captured a significant portion of the eClinical solutions market in 2024. Asia Pacific is projected to expand at the fastest CAGR during the forecast period. Received $8 million strategic investment from Mitsui & Co. Ltd. to expand in Asia Pacific. In November 2024, several AI-based Healthcare Innovations were introduced by a leading provider of cloud-based electronic health records (EHR) and practice management solutions, eClinicalWorks. The eClinical solutions market refers to the production, distribution, and use of eClinical solutions, which firstly targets physician practices and allows physicians to view and use as much or as little personal wellness data, with the patient's consent, as they want. eClinical solutions include electronic data capture (EDC), clinical trial management systems (CDMS), randomization and trial supply management (RTSM), and electronic patient-reported outcomes (ePRO). Integration of advanced technologies like machine learning (ML), artificial intelligence (AI), and cloud computing in eClinical solutions improves trial management and data processing modeling continually. eClinical solutions' industry-leading data and analytics platform and biometrics services experts help biopharma researchers at mid-size, large, and emerging life sciences organizations manage trial complexity with fewer resources and less time. The benefits of eClinical solutions include improving trials from acquisition to submission, quickening cycle times, improving productivity, and bringing out tomorrow's breakthroughs. Ottawa, May 06, 2025 (GLOBE NEWSWIRE) -- According to Statifacts, the global eClinical solutions market size surpassed USD 10,730 million in 2024 and is estimated to attain USD 40,500 million by 2034, growing at a CAGR of 14.2% during the forecast period from 2025 to 2034. The eClinical solutions market growth is driven by rising R&D expenditure across the globe, rising adoption of software solutions across the globe, and increasing demand for clinical trials outsourcing. The global eClinical solutions market size is predicted to increase from USD 12,260 million in 2025 and is anticipated to be worth around USD 40,500 million by 2034, expanding at a CAGR of 14.2% from 2025 to 2034. A study published by Statifacts a sister firm of Precedence Research. Story Continues Major Key Trends in the eClinical Solutions Market: Focus on patient-oriented solutions: eClinical solutions improve data accuracy, efficiency, and patient engagement in decentralized clinical trials for more efficient, faster research that brings hope to those who need it most. As compared to traditional trials, patients need to go to a specific clinical site, eClinical solutions, like virtual tools and technologies, making it easier for patients to participate from the comfort of their homes. Rising adoption of telemedicine and remote monitoring: Telemedicine improves self-management, physical activity, and rehabilitation. Telemedicine increases access to continuity and care services for cancer patients, reduces ED times, better medication adherence, and enhances satisfaction scores. Order the Premium Databook Today at the Discounted Rate of $1550! Limitations & Challenges in the eClinical Solutions Market: Data security and privacy issues: Data security and privacy issues in clinical trials can be caused by many behaviors, including significant carelessness, intentional or unintentional non-compliance, misconduct, and fraud. They can compromise the validity of the study results. Lack of awareness of eClinical solutions: Lack of awareness of clinical trials can be a reason for lower patient participation. Lack of awareness can reduce recruitment for cancer clinical trials. Development of eClinical Solutions Platforms: Market's Largest Potential eClinical solutions platforms are a type of randomized clinical trial that enables the simultaneous comparison of many intervention groups against a single control group that acts as a common based on a prespecified interim analysis plan. eClinical solutions platform transforms healthcare management with HMS/HER software, pharmacy management system, and LIMS. eClinical solutions platform built for IVF/fertility, dental, mental health, and medical health clinics. In September 2023, the eClinical Platform App in China, ensuring full compliance and accessibility, was launched by a leading global provider of innovative solutions for patient engagement and data collection in clinical trials, Datacubed Health. eClinical Solutions Market Scope Report Attribute Key Statistics Market Size in 2025 USD 12,260 Million Market Size by 2034 USD 40,500 Million Growth Rate from 2025 to 2034 CAGR of 14.2% Largest Market North America Fastest Growing Market Asia Pacific Base Year 2024 Forecast Period 2025 to 2034 Segments Covered By Product, By Delivery Mode, By Development Phase, By End-use, and By Region Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Regional Analysis: North America held the Dominant position: Technological Advancement to Support Growth North America dominated the global eClinical solutions market in 2024. Changing lifestyle, rising target population, rising adoption of information on patient health through eClinical solutions, and rising digitalization are driving the growth of the market in North America. Major Factors for the Market's Expansion in North America In June 2024, a new digital bank for the US healthcare industry, powered by Finastra, was launched by Bank Midwest. In April 2025, the launch of the CORE 500 Digital Stethoscope and Eko+ membership in Canada was announced by Eko Health. Strategic Investments & Acquisitions in North America Ascertain: In May 2025, Ascertain, a healthcare startup led by former Amazon executive Dr. Mark Michalski, secured $10 million in Series A funding . The investment was led by Deerfield Management and aims to enhance healthcare administration using AI agents. Science 37: In March 2024, Science 37, a company specializing in decentralized clinical trials, was acquired by eMed, LLC. This acquisition enhances eMed's capabilities in telehealth and diagnostics, expanding its reach in the e-clinical solutions market. Syneos Health: In March 2023, Syneos Health signed a multi-year deal to collaborate with Microsoft Research in developing a platform to leverage machine learning for the optimization of clinical trials. This partnership aims to enhance Syneos Health's capabilities in providing e-clinical solutions. What Expect from Asian Countries till 2034? Asia Pacific is projected to host the fastest-growing market in the coming years. Rising R&D spending across the globe, rising software solutions adoption in clinical trials, and increasing government funding in clinical trials are driving the growth of the eClinical solutions market in the Asia Pacific region. Top Asian Countries for eClinical Solutions India: In February 2025, the India Digital Health Activator, a new initiative to accelerate digital health adoption, interoperability, and innovation through public-private collaboration, was launched by the World Economic Forum (WEF). Japan: In February 2025, to revolutionize digital transformation in Japan's life sciences sector, the global leader in enterprise validation lifecycle management systems (VLMS), ValGenesis Inc., and Hitachi Industry & Control Solutions, Ltd., collaborated. eClinical Solutions Market Segmentation Insights Product Insights The clinical trial management system (CTMS) segment held a dominant presence in the eClinical solutions market in 2024. The benefits of CTMS include access to up-to-date and accurate study information. A CTMS automates and centralizes various trial management functions from planning to study closure. CTMS helps teams ensure regulatory compliance, reduce errors, and enhance collaboration by providing a single source of truth for all trial data. The electronic clinical outcome assessment (eCOA) segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034. The eCOA application is designed to accurately capture PRO data. It offers a range of customizable assessments and diaries tailored to meet the specific requirements of each clinical trial. End Use Insights The Contract Research Organizations (CROs) segment accounted for a considerable share of the eClinical solutions market in 2024. The CRO provides clinical, scientific, and business continuity for clinical trial sponsors. In advancing clinical research, CRO play an important role. They provide a controlled and structured environment to test new drugs, treatments, and other medical devices before being approved for widespread use. The pharma & biotech organizations segment is projected to experience the highest growth rate in the market between 2024 to 2034. Pharma & biotech organizations have a major role in drug discovery and development for the understanding of many diseases and their new treatment strategies and therapeutic interventions. Delivery Mode Insights The web and cloud-based segment led the eClinical solutions market. The benefits of web and cloud-based clinical solutions include reducing the risk of data loss, reducing network equipment & staff costs, increasing patient data accessibility, automating data scalability & processing, and accelerating clinical analyses and care processes. On-premises segment is set to experience the fastest rate of market growth from 2025 to 2034. On-premises storage can ensure the security and accessibility of sensitive patient data. It offers full control over data, customization options, and improved security. Development Phase Insights The Phase III segment registered its dominance over the eClinical solutions market in 2024. Phase III trial collects comprehensive safety data, enabling researchers and regulatory authorities to make informed decisions about the benefits of the drug versus its potential risks. The Phase I segment is anticipated to grow with the highest CAGR in the market during the studied years. Phase I studies of a new drug are generally the first that involve people. Phase I studies are used to find the highest dose of the new treatment that can be given safely without causing severe side effects. Browse More Research Reports: The U.S. eClinical solutions market size surpassed USD 3,840 million in 2024 and is predicted to reach around USD 13,010 million by 2034, registering a CAGR of 12.98% from 2025 to 2034. The U.S. preclinical CRO market size accounted for USD 2,120 million in 2024 and is expected to exceed around USD 4,660 million by 2034, growing at a CAGR of 8.2% from 2025 to 2034. The global medical device clinical trials market size was valued at USD 17.19 billion in 2024 and is expected to hit around USD 31.34 billion by 2034 with a CAGR of 6.19% from 2025 to 2034. The U.S. clinical workflow solutions market size is calculated at USD 3,600 million in 2024 and is predicted to reach around USD 16,160 million by 2034, expanding at a CAGR of 16.2% from 2025 to 2034. Order the Premium Databook Today at the Discounted Rate of $1550! eClinical Solutions Market Top Companies: Fountayn, formerly known as Datatrak International, Inc. Oracle Calyx, formerly part of Parexel International Corporation Medidata (Dassault Systemes) CRF Health (Signant Health) Clario (ERT and Bioclinica) eClinicalWorks Merative (IBM Watson Health) Anju Software eClinical Solutions MaxisIT IQVIA Castor Veeva Systems Recent Breakthroughs in the Global eClinical Solutions Market: In March 2025, the tech-driven Aayu Chemist app and Medcords platform from Medcords Healthcare Solutions were launched by Entero Healthcare. In July 2024, the North American launch of the Integrated Solution for Digital Transformation in Pathology was announced by AGFA HealthCare and Corista. Segments Covered in the Report By Product Electronic Data Capture (EDC) and Clinical Data Management Systems (CDMS) Clinical Trial Management Systems (CTMS) Clinical Analytics Platforms Randomization and Trial Supply Management (RTSM) Clinical Data Integration Platforms Electronic Clinical Outcome Assessment (eCOA) Safety Solutions Electronic Trial Master File (eTMF) Electronic Consent (eConsent) By Delivery Mode Cloud and Web Based On-Premise By Development Phase Phase I Phase II Phase III Phase IV By End-use Hospitals/Healthcare providers Contract Research Organizations (CROs) Academic Institutes Pharma & Biotech Organizations Medical Device Manufacturers By Region North America Europe Asia Pacific Latin America Middle East & Africa You can place an order or ask any questions, please feel free to contact us at sales@ Statifacts offers subscription services for data and analytics insights. This page provides options to explore and purchase a subscription tailored to your needs, granting access to valuable statistical resources and tools. Access here - Contact US Ballindamm 22, 20095 Hamburg, Germany Web: Europe: +44 7383 092 044 About US Statifacts is a leading provider of comprehensive market research and analytics services, offering over 1,000,000 market and custoer data sets across various industries. Their platform enables businesses to make informed strategic decisions by providing full access to statistics, downloadable in formats such as XLS, PDF, and PNG. Our Trusted Data Partners: Precedence Research | Towards Healthcare | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Dental | Towards EV Solutions | Nova One Advisor
Yahoo
06-05-2025
- Business
- Yahoo
Geno Stone agrees to pay cut with Bengals
Bengals safety Geno Stone will remain with Cincinnati in 2025 on a reduced contract. Per Jason Fitzgerald of Stone has accepted a pay cut for the coming year. Initially slated to make $6.475 million in 2025, Stone has agreed to a $4.9 million deal with $1.5 million guaranteed. Advertisement Stone, 26, signed with Cincinnati last offseason on a two-year deal as a free agent. He started all 17 games for the club, recording six passes defensed with four interceptions. A seventh-round pick in 2020, Stone played his first four seasons with the Ravens. He has 12 career picks in 68 games.
Business Wire
29-04-2025
- Business
- Business Wire
Mindbreeze Announces Continued Availability on the GSA Schedule Contract, Empowering Government Agencies with AI-Driven Knowledge Management
CHICAGO--(BUSINESS WIRE)--Mindbreeze Corporation, a leading global provider of AI-based knowledge management solutions, is pleased to announce the continued availability of its flagship solution, Mindbreeze InSpire, through the U.S. General Services Administration (GSA) Schedule Contract. The renewal of this contract solidifies Mindbreeze's commitment to supporting federal agencies with secure, scalable, and AI-powered knowledge management solutions. The GSA Schedule Contract (#47QTCA20D008P) remains valid through April 6, 2030. It enables U.S. government organizations to conveniently procure Mindbreeze's cutting-edge services and products through a streamlined, pre-approved procurement process. These schedules are vital in giving governments access to carefully vetted and accredited technologies at the federal, state, and municipal levels. 'Our continued inclusion on the GSA Schedule represents a strong vote of confidence in our technology and services,' said Daniel Fallmann, Founder and CEO of Mindbreeze. 'Often, government agencies face roadblocks regarding technological changes due to rules and regulations. We are proud to support government agencies in their mission-critical work by delivering solutions that unlock the value of information and enhance decision-making.' Mindbreeze solutions available through the GSA Schedule include: Mindbreeze InSpire Appliance and SaaS deployment options Premium Support Services (24/5 and 24/7) Implementation and Operation Services Certified Expert Training Programs Mindbreeze InSpire helps organizations analyze, understand, and organize their data through advanced artificial intelligence and machine learning capabilities. It turns information into actionable insight while maintaining compliance with the highest standards of security and reliability. About Mindbreeze Mindbreeze is a global leader in AI-powered enterprise intelligence, with headquarters in Europe and the U.S. Mindbreeze InSpire redefines how organizations access and utilize information. Powered by advanced AI, it transforms complex data into actionable insights, seamlessly connecting and analyzing information across systems. Unlike traditional solutions, our AI agents deliver hyper-relevant, context-aware insights tailored to unique business needs, enabling smarter, faster decision-making. With unmatched integration capabilities, data security, and automation at its core, Mindbreeze InSpire maximizes the value of your information ecosystem while driving innovation. Trusted by industry leaders and recognized for our cutting-edge technology, Mindbreeze leads the way in unlocking new dimensions of enterprise intelligence. Learn more at or follow us on LinkedIn and X @Mindbreeze.
